#206 PDF IF 3.50

Omalizumab for patients with chronic spontaneous urticaria: a narrative review of current status

Reviews

Bibliographic Details

Authors
Casale, T. B., Giménez-Arnau, A. M., Bernstein, J. A., Holden, M., Zuberbier, T., Maurer, M. + Corresponding author
Corresponding Author(s) +
Casale, T. B.
Journal / Publisher
Dermatol. Ther
Publication Date
2023
Volume / Edition
13
Pages
2573-2588
Impact Factor
3.50

Citation

Casale, T. B., Giménez-Arnau, A. M., Bernstein, J. A., Holden, M., Zuberbier, T., Maurer, M.: Omalizumab for patients with chronic spontaneous urticaria: a narrative review of current status. Dermatol. Ther 2023: 13; 2573-2588. IF: 3.50